Literature DB >> 20864568

Galectin multimerization and lattice formation are regulated by linker region structure.

Lesley A Earl1, Shuguang Bi, Linda G Baum.   

Abstract

Galectins regulate cellular functions by binding to glycan ligands on cell surface glycoprotein receptors. Prototype galectins, such as galectin-1, are one carbohydrate recognition domain (CRD) monomers that noncovalently dimerize, whereas tandem-repeat galectins, such as galectin-9, have two non-identical CRDs connected by a linker domain. Dimerization of prototype galectins, or both CRDs in tandem-repeat galectins, is typically required for the crosslinking of glycoprotein receptors and subsequent cellular signaling. Several studies have found that tandem-repeat galectins are more potent than prototype galectins in triggering many cell responses, including cell death. These differences could be due to CRD specificity, the presence or absence of a linker domain between CRDs, or both. To interrogate the basis for the increased potency of tandem-repeat galectins compared with prototype galectins in triggering cell death, we created three tandem-repeat galectin constructs with different linker regions joining identical galectin-1 CRDs, so that any differences we observed would be due to the contribution of the linker region rather than due to CRD specificity. We found that random-coil or rigid α-helical linkers that permit separation of the two galectin-1 CRDs facilitated the formation of higher-order galectin multimers and that these galectins were more potent in binding to glycan ligands and cell surface glycoprotein receptors, as well as triggering T cell death, compared with native galectin-1 or a construct with a short rigid linker. Thus, the increased potency of tandem-repeat galectins compared with prototype galectins is likely due to the ability of the linker domain to permit intermolecular CRD interactions, resulting in the formation of higher-order multimers with increased valency, rather than differences in CRD specificity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20864568      PMCID: PMC2998985          DOI: 10.1093/glycob/cwq144

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  37 in total

1.  Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity.

Authors:  Miki Sato; Nozomu Nishi; Hiroki Shoji; Masako Seki; Tomomi Hashidate; Jun Hirabayashi; Ken-ichi Kasai Ki; Yuiro Hata; Shigehiko Suzuki; Mitsuomi Hirashima; Takanori Nakamura
Journal:  Glycobiology       Date:  2002-03       Impact factor: 4.313

2.  Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells.

Authors:  Sean R Stowell; Sougata Karmakar; Caleb J Stowell; Marcelo Dias-Baruffi; Rodger P McEver; Richard D Cummings
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

3.  Carbohydrate-recognition domains of galectin-9 are involved in intermolecular interaction with galectin-9 itself and other members of the galectin family.

Authors:  Nobumitsu Miyanishi; Nozomu Nishi; Hiroko Abe; Yumiko Kashio; Rika Shinonaga; Shin-ichi Nakakita; Wataru Sumiyoshi; Akira Yamauchi; Takanori Nakamura; Mitsuomi Hirashima; Jun Hirabayashi
Journal:  Glycobiology       Date:  2007-01-12       Impact factor: 4.313

4.  Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways.

Authors:  Shuguang Bi; Lesley A Earl; Linsey Jacobs; Linda G Baum
Journal:  J Biol Chem       Date:  2008-02-07       Impact factor: 5.157

5.  Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface.

Authors:  Susanne Carlsson; Christopher T Oberg; Michael C Carlsson; Anders Sundin; Ulf J Nilsson; David Smith; Richard D Cummings; Jenny Almkvist; Anna Karlsson; Hakon Leffler
Journal:  Glycobiology       Date:  2007-03-05       Impact factor: 4.313

6.  Characterization of galectin-9-induced death of Jurkat T cells.

Authors:  Liang-Hao Lu; Ryusuke Nakagawa; Yumiko Kashio; Aiko Ito; Hiroki Shoji; Nozomu Nishi; Mitsuomi Hirashima; Akira Yamauchi; Takanori Nakamura
Journal:  J Biochem       Date:  2006-12-13       Impact factor: 3.387

7.  Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion.

Authors:  Sean R Stowell; Yuning Qian; Sougata Karmakar; Natalia S Koyama; Marcelo Dias-Baruffi; Hakon Leffler; Rodger P McEver; Richard D Cummings
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

8.  Galectin-8 induces apoptosis in the CD4(high)CD8(high) thymocyte subpopulation.

Authors:  María Virginia Tribulatti; Juan Mucci; Valentina Cattaneo; Fernán Agüero; Tim Gilmartin; Steven R Head; Oscar Campetella
Journal:  Glycobiology       Date:  2007-09-24       Impact factor: 4.313

9.  Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling.

Authors:  I-Ju Chen; Hung-Lin Chen; Michael Demetriou
Journal:  J Biol Chem       Date:  2007-09-26       Impact factor: 5.157

10.  Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation.

Authors:  Ken S Lau; Emily A Partridge; Ani Grigorian; Cristina I Silvescu; Vernon N Reinhold; Michael Demetriou; James W Dennis
Journal:  Cell       Date:  2007-04-06       Impact factor: 41.582

View more
  43 in total

1.  Burn control, an adipocyte-specific function for galectin-12.

Authors:  Linda G Baum
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-04       Impact factor: 11.205

2.  In silico designing, cloning, and heterologous expression of novel chimeric human B lymphocyte CD20 extra loop.

Authors:  Mahdi Fasihi-Ramandi; Jafar Amani; Ali-Hatef Salmanian; Seyed Mohammad Moazzeni; Kazem Ahmadi
Journal:  Tumour Biol       Date:  2016-06-27

Review 3.  Galectin-1 research in T cell immunity: past, present and future.

Authors:  Filiberto Cedeno-Laurent; Charles J Dimitroff
Journal:  Clin Immunol       Date:  2011-10-06       Impact factor: 3.969

4.  How altering the modular architecture affects aspects of lectin activity: case study on human galectin-1.

Authors:  Tanja J Kutzner; Adele Gabba; Forrest G FitzGerald; Nadezhda V Shilova; Gabriel García Caballero; Anna-Kristin Ludwig; Joachim C Manning; Clemens Knospe; Herbert Kaltner; Fred Sinowatz; Paul V Murphy; Mare Cudic; Nicolai V Bovin; Hans-Joachim Gabius
Journal:  Glycobiology       Date:  2019-07-19       Impact factor: 4.313

5.  Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry.

Authors:  Shuguang Bi; Patrick W Hong; Benhur Lee; Linda G Baum
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

Review 6.  The bisecting GlcNAc in cell growth control and tumor progression.

Authors:  Hazuki E Miwa; Yinghui Song; Richard Alvarez; Richard D Cummings; Pamela Stanley
Journal:  Glycoconj J       Date:  2012-04-04       Impact factor: 2.916

7.  Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.

Authors:  N Mazurek; J C Byrd; Y Sun; M Hafley; K Ramirez; J Burks; R S Bresalier
Journal:  Cell Death Differ       Date:  2011-09-23       Impact factor: 15.828

8.  A chimeric, multivalent assembly of galectin-1 and galectin-3 with enhanced extracellular activity.

Authors:  Margaret M Fettis; Shaheen A Farhadi; Gregory A Hudalla
Journal:  Biomater Sci       Date:  2019-04-23       Impact factor: 6.843

Review 9.  Key regulators of galectin-glycan interactions.

Authors:  Nourine A Kamili; Connie M Arthur; Christian Gerner-Smidt; Eden Tafesse; Anna Blenda; Marcelo Dias-Baruffi; Sean R Stowell
Journal:  Proteomics       Date:  2016-12       Impact factor: 3.984

Review 10.  The regulatory power of glycans and their binding partners in immunity.

Authors:  Jenny L Johnson; Mark B Jones; Sean O Ryan; Brian A Cobb
Journal:  Trends Immunol       Date:  2013-02-26       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.